Dr. Carlos Joseph T. Panaligan Jr.

Dr. Carlos Joseph T. Panaligan Jr.
MD, FPBA

Make An Appointment

Designation

Consultant Anesthesiologist

Speciality

Consultant Anesthesiologist

Qualification

-

License number

-

Languages

English, Tagalog

Location

-

About the Doctor

Dr. Carlos Joseph Panaligan Jr. is a board-certified anesthesiologist with over 20 years of experience in perioperative care, pain management, and hospital-based anesthesia services.

He completed his Doctor of Medicine at Far Eastern University – Nicanor Reyes Medical Foundation and underwent post-graduate internship at Veterans Memorial Hospital, Quezon City. He completed his residency training in Anesthesiology at the University of the Philippines – Philippine General Hospital from 2001 to 2003.

Dr. Panaligan passed all required written, oral, and practical board exams in anesthesiology between 2004 and 2006 and has been practicing ever since.

He is a Fellow of the Philippine Board of Anesthesiology (FPBA) and a member of several professional organizations.

Procedure focus

  • Chemotherapy
  • Targeted Therapy
  • Immunotherapy
  • Hormonal Therapy
  • Intensity Modulated Radiotherapy (IMRT)
  • Stereotactic Radiotherapy (SRT)
  • Stereotactic Radiosurgery (SRS)
  • Stereotactic Body Radiation Therapy (SBRT)
  • Intraoperative Radiotherapy (IORT)

General Oncology with Special Interest

  • Thyroid cancer
  • Breast cancer
Day
8:00 am – 12:00 pm
1:00 pm – 5:00 pm
Monday
-
-
Tuesday
-
by appointment
Wednesday
-
-
Thursday
by appointment
-
Friday
-
-
To schedule an appointment, please call or text 0917-899-6626
  • Fellow of the Royal College of Physician, London, England
  • Fellow of the Royal College of Radiologists, London, England
  • Fellowship in Radiation Oncology, University of Toronto, Canada
  • Previous member of the United Kingdom National Cancer Research Institute in designing and managing national trials head and neck and thyroid cancers
  • 1st prize: Presentation on Intensity Modulated Radiotherapy for Thyroid Cancers in the 2nd World Thyroid Cancer Congress, Toronto Canada in 2013
  • Clinical Excellent award at The Christie NHS Foundation Trust 2006
  • Chief investigator: Phase 3 randomised of XL-184 (Cabozantinib) versus placebo in unresectable, locally advanced or metastatic thyroid medullary carcinoma
  • Principal investigator: Phase 3 PARSPORT (parotid sparing radiotherapy) in Head and neck cancer.
  • Principal investigator: Phase 3 HILO trial. High dose versus low dose radioiodine with or without recombinant human thyroid stimulating hormone for remnant ablation following surgery for differentiated thyroid cancer.
  • Principal investigator: Phase 3 ION trial. Is radioiodine ablation necessary in low risk thyroid cancers. Principal investigator. Phase 3 randomised trial using sorafenib versus placebo in metastatic differentiated thyroid cancer refractory to radioiodine therapy.
  • Principal investigator: Phase 3 randomized trial Determination of Quality of Life Instrument most preferred by patients with thyroid cancer (DETEQT)
  • Principal investigator: Phase 3 randomised trial to compare the effects of two doses of vandetanib (150mg Vs 300mg) in patients with advanced medullary thyroid cancer
  • Co-investigator: Phase 2 EXTREME study (Cetuximab and platinum based chemotherapy in recurrent or metastatic head and neck cancers.
  • Co-investigator: Phase 2 synchronous Capecitabine and radiotherapy in locally advanced head and neck cancers.
  • Co-investigator: Phase 3 randomised trial of zalutumumab with best supportive care in patients with non-curable head and neck squamous cell carcinoma who have failed standard platinum based chemotherapy.
  • Co-investigator. Phase I/II radiotherapy dose escalation and cetuximab study in intermediate stage head and neck cancer. (INTENSE)
  • Co-investigator. X-ray volumetric imaging of parotid to enable dose monitoring during parotid sparing intensity modulated radiotherapy (X-PERT)
  • Co-investigator. Study of the impact of co-registering CT and MRI compared with CT alone in the planning of head and neck carcinoma (PRECISE)
  • Craniospinal Radiotherapy in a man with Severe Kyphoscoliosis. B K Yap, B Magee, E Vollans. Clin Onc (2001) 13: 117-119,
  • Are serial bone scans useful for the follow-up of clinically localized, low to intermediate grade, prostate cancer managed with a watchful observation protocol? B K Yap, R Choo, G DeBoer, L Klotz, C Danjoux, G Morton. BJU International, 2003 May; 91 (7): 613-7.
  • Barium paste: Useful in primary tumour localisation in oral cancer. B K Yap and N J Slevin. Br J Radiol. 2004 Feb; 77(914):143-5.
  • Cribriform-morular variant of papillary thyroid carcinoma: molecular characterization of a case with neuroendocrine differentiation and aggressive behavior. Cameselle-Teijeiro J, Menasce LP, Yap BK, Colaco RJ, Castro P, Celestino R, Ruíz-Ponte C, Soares P, Sobrinho-Simões M. Am J Clin Pathol. 2009 Jan; 131(1):134-42.
  • Patterns of relapse following radiotherapy for differentiated thyroid cancer: implication for target volume delineation. Azrif M, Slevin NJ, Sykes AJ, Swindell R, Yap BK. Radiother Oncol. 2008 Oct;89(1):105-13. 2008 Jun 23.
  • IMRT dose fractionation for head and neck cancer: variation in current approaches will make standardisation difficult. Ho KF, Fowler JF, Sykes AJ, Yap BK, Lee LW, Slevin NJ. Acta Oncol. 2009;48(3):431-9.
  • A clinical case report of cribriform-morular variant of papillary thyroid carcinoma with neuroendocrine differentiation and aggressive behaviour in a patient with familial adenomatous polyposis coli. R.J. Colaco, L.P. Menasce, M. Ranson, M. Sobrinho Simoes, J. Cameselle Teijeiro, S. Vinjamuri, and B. K. Yap. Thyroid Science 4(3):CR1-3, 2009
  • Can synchronous chemotherapy be added to accelerated hypofractionated radiotherapy in patients with base of tongue cancer? Jegannathen A, Swindell R, Yap BK, Lee L, Sykes A, Mais K, Slevin, N. Clin Oncol 2010; 22(3): 185-191.
  • Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer. Mallick U, Harmer C, Yap BK, Wadsley J, Clarke S, Moss L, Nicol A, Clark PM, Farnell K, McCready R, Smellie J, Franklyn JA, John R, Nutting CM, Newbold K, Lemon C, Gerrard G, Abdel-Hamid A, Hardman J, Macias E, Roques T, Whitaker S, Vijayan R, Alvarez P, Beare S, Forsyth S, Kadalayil L, Hackshaw A. N Engl J Med. 2012 May 3;366(18):1674-85.
  • Monitoring dosimetric impact of weight loss with kilovoltage (kV) cone beam CT (CBCT) during parotid-sparing IMRT and concurrent chemotherapy. Ho KF, Marchant T, Moore C, Webster G, Rowbottom C, Penington H, Lee L, Yap BK, Sykes A, Slevin N. Int J Radiat Oncol Biol Phys. 2012 Mar 1; 82(3):e375-82.
  • A double-blind, placebo-controlled, randomised trial of active manuka honey and standard oral care for radiation-induced oral mucositis. Bardy J, Molassiotis A, Ryder WD, Mais K, Sykes A, Yap BK, Lee L, Kaczmarski E, Slevin N. Br J Oral Maxillofac Surg. 2012 Apr; 50(3):221-6.
  • Evidence for extrathyroidal formation of 3-iodothyronamine in humans as provided by a novel monoclonal antibody-based chemiluminescent serum immunoassay. Hoefig CS, Köhrle J, Brabant G, Dixit K, Yap BK, Strasburger CJ, Wu Z. J Clin Endocrinol Metab. 2011 Jun;96(6):1864-72
  • Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. Nutting CM, Morden JP, Harrington KJ, Urbano TG, Bhide SA, Clark C, Miles EA, Miah AB, Newbold K, Tanay M, Adab F, Jefferies SJ, Scrase C, Yap BK, A’Hern RP, Sydenham MA, Emson M, Hall E; PARSPORT trial management group. Lancet Oncol. 2011 Feb;12(2):127-36
  • Effect of central compartment neck dissection on hypocalcaemia incidence after total thyroidectomy for carcinoma. Mitra I, Nichani JR, Yap BK, Homer JJ. J Laryngol Otol. 2011 May; 125(5):497-501.
  • Can synchronous chemotherapy be added to accelerated hypofractionated radiotherapy in patients with base of tongue cancer? Jegannathen A, Swindell R, Yap BK, Lee L, Sykes A, Mais K, Sanghera P, Hartley A, Glaholm J, Slevin N. Clin Oncol (R Coll Radiol). 2010 Apr;22(3):185-91
  • Nasopharyngeal carcinoma: a retrospective review of demographics, treatment and patient outcome in a single centre. Colaco RJ, Betts G, Donne A, Swindell R, Yap BK, Sykes AJ, Slevin NJ, Homer JJ, Lee LW. Clin Oncol (R Coll Radiol). 2013 Mar(3):171-7.
  • Phase II trial of sorafenib in advanced salivary adenoid cystic carcinoma of the head and neck. Thomson DJ, Silva P, Denton K, Bonington S, Mak SK, Swindell R, Homer J, Sykes AJ, Lee LW, Yap BK, Slevin NJ. Head Neck. 2013 Dec 17. doi: 10.1002/hed.23577.
  • Use of pre-ablation radioiodine-131 scan to assess the impact of surgical volume and specialization following thyroidectomy for differentiated thyroid carcinoma. Yap B K, Homer J, Parrott N, Loughran S, Murby B, Swindell R, Gandhi A. Eur Thyroid J 2013;2:275-281
  • Anaplastic Thyroid Cancer: The Addition of Systemic Chemotherapy to radiotherapy led to an observed improvement in survival—A Single Centre Experience and the Review of the Literature. Natalie M. Lowe, Sean Loughran, Nicholas J. Slevin, and Beng K. Yap. The Scientific World Journal; vol. 2014:1–8, 2014.
  • Carotid dosimetry for T1 glottic cancer radiotherapy. Garcez K, Lim CC, Whitehurst P, Thomson D, Ho KF, Lowe M, Sykes A, Lee L, Yap B, Slevin N. Br J Radiol. 2014 Feb 17:20130754
  • Postoperative Management of Thyroid Cancer. Tips and Tricks in Endocrine Surgery. Beng K Yap; 2014, pp 205-212. ISBN: 978-0-85729-982-6 (Print) 978-1-4471-2146-6 (Online)
  • No adverse affect in clinical outcome using low pre-ablation diagnostic 131I activity in differentiated thyroid cancer: refuting thyroid stunning effect. Yap Beng K & Murby B. J Clin Endo Metab, 2014 Feb
  • Thyroid incidentalomas discovered on positron emission tomography CT scanning – Malignancy rate and significance of standardised uptake values. Brindle R, Mullan D, Yap BK, Gandhi A. Eur J Surg Oncol: 2014.
  • Management Of The Compromised Airway And The Role Of Tracheostomy In Anaplastic Thyroid Carcinoma. Navin Mani, Katherine McNamara, Natalie Lowe, Sean Loughran, Beng K Yap. Head & Neck; 2014
  • Evaluation of an automatic segmentation algorithm for definition of head and neck organs at risk. David Thomson, Chris Boylan, Tom Liptrot, Adam Aitkenhead, Lip Lee, Beng Yap, Andrew Sykes, Carl Rowbottom, Nicholas Slevin. Radiation Oncology 2014
  • Dose intensified hypofractionated intensity-modulated radiotherapy with synchronous cetuximab for intermediate stage head and neck squamous cell carcinoma. David J Thomson, Kean F Ho, Linda Ashcroft, Kim Denton, Guy Betts, Kathleen L Mais, Kate Garcez, Beng K Yap, Lip W Lee, Andrew J Sykes, Carl G Rowbottom, Nicholas J Slevin. Acta Oncologica 2015: 54(1): 88=98
  • Variations in single/two stage thyroidectomies for cancer may be due to differences in thyroid fine needle cytology provision. A Gandhi, B Ranganathan, SA Thiryayi, M Rowland, Beng K Yap. Eur J Surg Oncol 2015
  • Surgical management of medullary thyroid cancer: which guidelines should we follow? Alex Bowen, Navin Mani, Susannah Penney, Sean Loughran, Beng Yap. J Laryng Otolog 2015.
  • Cisplatin plus Capecitabine as First-Line Chemotherapy for Recurrent or Metastatic Head and Neck Squamous Cell Cancer: Experience Outside of a Trial Setting. Andrew J McPartlin, K Mais, C Barker, Ric Swindell, K Mitchell, A Sykes, L Lee, B Yap, Nicholas J Slevin. Chemotherapy 2013;59(1): 1-7.
  • Roles of Ki67 in Breast cancer-Important for management? CH Yip; N Bhoo-Pathy; JM Daniel; YC Foo; AK Mohamed; MM Abdullah; YS Ng; BK Yap; R Pathmanathan: Volume 17, Issue 3, March 2016, Page 1077-1082
  • The role of neoadjuvant chemotherapy in the surgical management of women with breast cancer in a middle-income country.Cheng-Har Yip, Mastura Yusof, Matin Mellor Abdullah, Yoke-Ching Foo, Beng-Khiong Yap, Yi Siang Ng, Rajadurai Pathmanathan: Advances in Modern Oncology research: doi: 10.18282/amor.v3.is1.197
  • Retrospective Analysis of Cancer Care Performance and Survival Outcome for Nasopharyngeal Carcinoma at a leading Cancer Treatment Centre in Malaysia 2008-2012. Matin Mellor Abdullah, Yoke Ching Foo, Beng Khiong Yap, Catherine May Ling Lee, L P Hoo, Teck Onn Lim. Asian Pac J Cancer Prev, 20 (6), 1701-1708; June 2019
  • Real‐world multicenter study of the safety and efficacy of netupitant plus palonosetron fixed‐dose combination to prevent chemotherapy‐induced nausea and vomiting among Malaysian patients receiving moderately or highly emetogenic chemotherapy. Mastura Md Yusof, Matin Mellor Abdullah, Beng Khiong Yap, Soo Chin Ng: Asia-Pacific Journal of Clinical Oncology 18(9); Nov 2021